Characterizing the relationships between patient‐reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib

• DOI: 10.1111/jdv.17909
• Publication Date: 2022-01-09T17:09:58Z
• Authors: R. Winnette; A. Banerjee; V. Sikirica; E. Peeva; K. Wyrwich
• Keywords: Adult; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Alopecia Areata; Humans; Janus Kinase Inhibitors; Patient Reported Outcome Measures; Protein Kinase Inhibitors; Hair; 3. Good health

The phase 2a ALLEGRO trial (NCT02974868) investigated the safety and efficacy of ritlecitinib (PF-06651600) brepocitinib (PF-06700841) in adults with alopecia areata. No randomized controlled for areata has evaluated correlations between clinician-assessed hair loss patient-reported outcomes.Report scores from Alopecia Areata Symptom Impact Scale (AASIS; a outcome tool) explore relationships those Severity Tool (SALT) at baseline week 24 trial.Adults were to (n = 48), 47) or placebo 47). After weeks, mixed-effects model repeated measures was used calculate active treatment groups' AASIS score least-squares mean differences. Relationships SALT by Pearson's correlation coefficients using pooled data.Baseline similar among groups. Both groups reported significant improvements (least-squares differences vs. ritlecitinib, -0.8 -2.3; brepocitinib, -0.9 -3.7; P < 0.05 all). At 24, (standard deviation) improved compared [ritlecitinib, 54.4 (40.3) 89.4 (15.8); 31.9 (35.7) 86.4 (18.1)]. global subscale ranged 0.34 0.58; all.Patients significantly placebo. medium-to-large can be seen scores. Our experience instrument highlighted several aspects that suggest new tools are needed accurately assess patients' relevant related signs, symptoms daily functioning.